{"preliminary_commentary":{"by_channel":{"youtube":4,"x_thread":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06380751\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["saruparib (AZD5305)","camizestrant"],["camizestrant"],["saruparib (AZD5305)"]],"indication":"first-line BRCA1/BRCA2/PALB2-mutated HR-positive, HER2-negative advanced breast cancer","name":"EvoPAR-Breast01","nct_id":"NCT06380751","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evopar-breast01-nct06380751. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EvoPAR-BR01","arms":[{"description":"participants will receive saruparib (AZD5305) orally and camizestrant orally","label":"Arm 1: saruparib (AZD5305) plus camizestrant","type":"EXPERIMENTAL"},{"description":"agents are indicated below and should follow local guidelines:\n\n* Physician's Choice CDK4/6i:\n\n  * abemaciclib orally, or\n  * ribociclib orally, or\n  * palbociclib orally.\n* Physician's Choice ET:\n\n  * fulvestrant intramuscularly, or\n  * One of the following AIs:\n\n    * letrozole orally, or\n    * anastrozole orally, or\n    * exemestane orally","label":"Arm 2: Physician's choice CDK4/6i plus physician's choice ET","type":"ACTIVE_COMPARATOR"},{"description":"participants will receive camizestrant orally. Agents for CDK4/6i treatment are indicated above and should follow local guidelines","label":"Arm 3: Physician's choice CDK4/6i plus camizestrant","type":"EXPERIMENTAL"},{"description":"participants will receive Saruparib (AZD5305) plus -Physician's Choice ET:\n\n* fulvestrant intramuscularly, or\n* One of the following AIs:\n\n  * letrozole orally, or\n  * anastrozole orally, or\n  * exemestane orally","label":"Arm 4: Saruparib (AZD5305) plus physician's choice ET","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-12-30","type":"ESTIMATED"},"conditions":["Advanced Breast Cancer"],"enrollment":{"count":788,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Saruparib (AZD5305)","otherNames":[],"type":"DRUG"},{"name":"Camizestrant","otherNames":[],"type":"DRUG"},{"name":"Abemaciclib","otherNames":[],"type":"DRUG"},{"name":"Ribociclib","otherNames":[],"type":"DRUG"},{"name":"Palbociclib","otherNames":[],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Letrozole","otherNames":[],"type":"DRUG"},{"name":"Anastrozole","otherNames":[],"type":"DRUG"},{"name":"Exemestane","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"AstraZeneca","official_title":"A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12-18","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (Arm 1 vs arm 2)","timeFrame":"Up to approximately 64 months"}],"references":[],"start_date":{"date":"2024-08-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06380751"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evopar-breast01-nct06380751"}